GlassScriptPhysician profile
Marissa T Santos
NPI 1659332377
$18,191.33
in general payments reported to CMS, 2019-2025
39 companies · $2,785 in 2025
The $2,785 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,571 · 2020: $2,278 · 2021: $2,395 · 2022: $2,340 · 2023: $2,696 · 2024: $3,125 · 2025: $2,785.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,507 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,507.41 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,413.99 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $1,668.53 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,442.99 | 2019-2025 | Jardiance, Ofev |
| Lilly USA, LLC | $1,347.42 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amarin Pharma, INC. | $1,261.57 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,040.45 | 2019-2025 | Xifaxan, Cycloset, Trulance |
| Merck Sharp & Dohme LLC | $870.16 | 2019-2023 | Verquvo, Steglatro |
| Glaxosmithkline, LLC. | $708.69 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Kowa Pharmaceuticals America, INC. | $636.48 | 2019-2025 | Livalo, Seglentis, Zoryve |
| Gilead Sciences, INC. | $587.98 | 2020-2025 | |
| Astellas Pharma US INC | $534.90 | 2020-2025 | Veozah, Myrbetriq |
| Amgen INC. | $525.40 | 2019-2025 | Repatha, Otezla, Repatha |
| E.R. Squibb & Sons, L.L.C. | $466.60 | 2019-2024 | Eliquis, Camzyos |
| Exact Sciences Corporation | $449.56 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $407.24 | 2019-2025 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $381.13 | 2019-2022 | |
| Paratek Pharmaceuticals, INC. | $309.61 | 2021-2025 | Nuzyra |
| Phathom Pharmaceuticals, INC. | $287.62 | 2024-2025 | Voquezna |
| Sanofi-Aventis U.S. LLC | $212.68 | 2019-2020 | |
| Intra-Sana Laboratories | $196.62 | 2025 | Reltone 200 Mg, Reltone 400 Mg, Glycate |
| Allergan, INC. | $163.28 | 2019-2020 | |
| Esperion Therapeutics, INC. | $162.76 | 2021-2025 | Nexletol |
| Novartis Pharmaceuticals Corporation | $154.73 | 2019-2024 | |
| Hikma Pharmaceuticals USA | $139.82 | 2020-2023 | Ryaltris, Mitigare |
| Abbvie INC. | $123.22 | 2021-2024 | Qulipta, Ubrelvy |
| Takeda Pharmaceuticals U.S.A., INC. | $117.61 | 2019-2020 | |
| Ardelyx, INC. | $94.65 | 2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $71.66 | 2023-2024 | Linzess |
| Renalytix Ai, INC. | $66.76 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Abbott Laboratories | $59.58 | 2024-2025 | Freestyle Libre 3 |
| Genentech USA, INC. | $51.72 | 2020-2021 | |
| Avvisto Therapeutics, LLC | $39.27 | 2024 | Cycloset |
| Merz North America, INC. | $39.22 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $37.95 | 2019-2022 | |
| Csl Behring | $32.52 | 2024 | Kcentra |
| Arbor Pharmaceuticals, INC. | $29.81 | 2020-2022 | |
| Eyevance Pharmaceuticals LLC | $21.81 | 2021 | |
| Dermira, INC. | $17.90 | 2020 | |
| Mylan Specialty L.P. | $17.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marissa Santos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.